Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bedoradrine - Kissei Pharmaceutical/MediciNova

Drug Profile

Bedoradrine - Kissei Pharmaceutical/MediciNova

Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221

Latest Information Update: 24 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; MediciNova
  • Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute asthma
  • Phase I Chronic obstructive pulmonary disease
  • No development reported Preterm labour; Status asthmaticus

Most Recent Events

  • 01 Mar 2022 MediciNova has patent protection for Bedoradrine for Acute asthma in USA
  • 01 Mar 2022 MediciNova has patents pending for Bedoradrine in USA and other foreign countries
  • 15 Apr 2021 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (IV) (MediciNova pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top